230 related articles for article (PubMed ID: 19761834)
1. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.
Awasthi S; Lubinski JM; Friedman HM
Vaccine; 2009 Nov; 27(49):6845-53. PubMed ID: 19761834
[TBL] [Abstract][Full Text] [Related]
2. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.
Awasthi S; Lubinski JM; Shaw CE; Barrett SM; Cai M; Wang F; Betts M; Kingsley S; Distefano DJ; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
J Virol; 2011 Oct; 85(20):10472-86. PubMed ID: 21813597
[TBL] [Abstract][Full Text] [Related]
3. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
Awasthi S; Huang J; Shaw C; Friedman HM
J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
[TBL] [Abstract][Full Text] [Related]
4. Glycoprotein C of Herpes Simplex Virus 1 Shields Glycoprotein B from Antibody Neutralization.
Komala Sari T; Gianopulos KA; Nicola AV
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826995
[TBL] [Abstract][Full Text] [Related]
5. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.
Ramsey NLM; Visciano M; Hunte R; Loh LN; Burn Aschner C; Jacobs WR; Herold BC
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295919
[TBL] [Abstract][Full Text] [Related]
6. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection.
Judson KA; Lubinski JM; Jiang M; Chang Y; Eisenberg RJ; Cohen GH; Friedman HM
J Virol; 2003 Dec; 77(23):12639-45. PubMed ID: 14610186
[TBL] [Abstract][Full Text] [Related]
7. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.
Friedman HM; Wang L; Fishman NO; Lambris JD; Eisenberg RJ; Cohen GH; Lubinski J
J Virol; 1996 Jul; 70(7):4253-60. PubMed ID: 8676446
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
9. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
[TBL] [Abstract][Full Text] [Related]
10. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.
Halford WP; Püschel R; Gershburg E; Wilber A; Gershburg S; Rakowski B
PLoS One; 2011 Mar; 6(3):e17748. PubMed ID: 21412438
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
Hook LM; Cairns TM; Awasthi S; Brooks BD; Ditto NT; Eisenberg RJ; Cohen GH; Friedman HM
PLoS Pathog; 2018 May; 14(5):e1007095. PubMed ID: 29791513
[TBL] [Abstract][Full Text] [Related]
12. Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E.
Hook LM; Huang J; Jiang M; Hodinka R; Friedman HM
J Virol; 2008 Jul; 82(14):6935-41. PubMed ID: 18480440
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of interleukin-2 enhances the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D.
Li WR; Niu B; Wang JW; Feng ZJ; Wang DX
Acta Virol; 2006; 50(4):251-6. PubMed ID: 17177610
[TBL] [Abstract][Full Text] [Related]
14. Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.
Görander S; Harandi AM; Lindqvist M; Bergström T; Liljeqvist JÅ
J Virol; 2012 Jul; 86(14):7544-53. PubMed ID: 22553328
[TBL] [Abstract][Full Text] [Related]
15. Herpes simplex virus type 1 evades the effects of antibody and complement in vivo.
Lubinski JM; Jiang M; Hook L; Chang Y; Sarver C; Mastellos D; Lambris JD; Cohen GH; Eisenberg RJ; Friedman HM
J Virol; 2002 Sep; 76(18):9232-41. PubMed ID: 12186907
[TBL] [Abstract][Full Text] [Related]
16. Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD.
Baghian A; Chouljenko VN; D'Auvergne O; Newman MJ; Baghian S; Kousoulas KG
J Med Microbiol; 2002 Apr; 51(4):350-357. PubMed ID: 11926742
[TBL] [Abstract][Full Text] [Related]
17. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC.
Lubinski J; Wang L; Mastellos D; Sahu A; Lambris JD; Friedman HM
J Exp Med; 1999 Dec; 190(11):1637-46. PubMed ID: 10587354
[TBL] [Abstract][Full Text] [Related]
18. Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.
Gmyrek GB; Filiberti A; Montgomery M; Chitrakar A; Royer DJ; Carr DJJ
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999018
[TBL] [Abstract][Full Text] [Related]
19. Immune evasion by herpes simplex virus type 1, strategies for virus survival.
Friedman HM
Trans Am Clin Climatol Assoc; 2003; 114():103-12. PubMed ID: 12813914
[TBL] [Abstract][Full Text] [Related]
20. Degradation of Quillaja saponaria Molina saponins: loss of the protective effects of a herpes simplex virus 1 subunit vaccine.
Marcian DJ; Ptak RG; Voss TG; Reynolds RC; Pathak AK; Chamblin TL; Scholl DR; May RD
Int Immunopharmacol; 2002 Nov; 2(12):1703-11. PubMed ID: 12469944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
